Cognition Therapeutics, Inc. (CGTX) Current Ratio
- Current ratio · latest quarter: Value 7.03×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.03× | Current assets / current liabilities. $38.30M ÷ $5.45M ≈ 7.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 38.30M USD | Assets, Current |
| Current obligations | 5.45M USD | Liabilities, Current |
| Cash and equivalents | 34.01M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 673.00K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.30M | $5.45M | $34.01M | (m) | (m) | (m) | $673.00K | (m) | 7.03× |
| 2026-03-31 | $35.81M | $6.05M | $31.13M | (m) | (m) | (m) | $3.85M | (m) | 5.92× |
| 2025-12-31 | $47.99M | $13.92M | $36.81M | (m) | (m) | (m) | $1.12M | (m) | 3.45× |
| 2025-09-30 | $42.88M | $6.65M | $39.33M | (m) | (m) | (m) | $827.00K | (m) | 6.44× |
| 2025-06-30 | $19.05M | $12.36M | $10.74M | (m) | (m) | (m) | $771.00K | (m) | 1.54× |
| 2025-03-31 | $22.87M | $10.95M | $16.43M | (m) | (m) | (m) | $1.82M | (m) | 2.09× |
| 2024-12-31 | $29.55M | $11.14M | $25.01M | (m) | (m) | (m) | $1.98M | (m) | 2.65× |
| 2024-09-30 | $26.83M | $12.71M | $22.01M | (m) | (m) | (m) | $1.90M | (m) | 2.11× |
| 2024-06-30 | $33.55M | $10.92M | $28.53M | (m) | (m) | (m) | $3.03M | (m) | 3.07× |
| 2024-03-31 | $37.97M | $9.50M | $34.67M | (m) | (m) | (m) | $2.64M | (m) | 4.00× |
| 2023-12-31 | $34.22M | $10.17M | $29.92M | (m) | (m) | (m) | $3.69M | (m) | 3.37× |
| 2023-09-30 | $36.04M | $8.23M | $32.97M | (m) | (m) | (m) | $2.86M | (m) | 4.38× |
| 2023-06-30 | $41.55M | $7.91M | $37.19M | (m) | (m) | (m) | $4.06M | (m) | 5.25× |
| 2023-03-31 | $42.80M | $7.46M | $38.81M | (m) | (m) | (m) | $3.12M | (m) | 5.73× |
| 2022-12-31 | $47.65M | $7.79M | $41.56M | (m) | (m) | (m) | $3.22M | (m) | 6.11× |
| 2022-09-30 | $50.93M | $12.12M | $46.61M | (m) | (m) | (m) | $8.09M | (m) | 4.20× |
| 2022-06-30 | $50.74M | $6.82M | $45.77M | (m) | (m) | (m) | $3.30M | (m) | 7.44× |
| 2022-03-31 | $56.44M | $7.64M | $51.51M | (m) | (m) | (m) | $4.00M | (m) | 7.38× |
| 2021-12-31 | $58.99M | $7.86M | $54.72M | (m) | (m) | (m) | $4.17M | (m) | 7.50× |
| 2021-09-30 | $10.04M | $4.43M | $8.31M | (m) | (m) | (m) | $2.77M | (m) | 2.27× |
| 2020-12-31 | $6.91M | $3.25M | $5.19M | (m) | (m) | (m) | $2.00M | (m) | 2.13× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |